Zentalis, On Sunday, Announced Interim DENALI Part 1b Data Showing Median Overall Survival Of 15.8 Months With Azenosertib Monotherapy In Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Loading news article.

Zentalis, On Sunday, Announced Interim DENALI Part 1b Data Showing Median Overall Survival Of 15.8 Months With Azenosertib Monotherapy In Cyclin E1-Positive Platinum-Resistant Ovarian Cancer | WAPE

Zentalis, On Sunday, Announced Interim DENALI Part 1b Data Showing Median Overall Survival Of 15.8 Months With Azenosertib Monotherapy In Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Article summary

Related companies

Analyzed by WAPE AI.

Comments —